HALF: Prospective multi-centre phase II clinical trial
evaluating the efficacy and safety of tyrosine kinase
inhibitors discontinuation after two-step dose reduction in
patients with chronic myeloid leukemia in deep molecular
remission.

a 2022

HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

ŽÁČKOVÁ, Daniela, Petra ČIČÁTKOVÁ, Edgar FABER, Lukáš STEJSKAL, Michal KARAS et. al.

Basic information

Original name

HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

Authors

ŽÁČKOVÁ, Daniela (203 Czech Republic, guarantor, belonging to the institution), Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution), Edgar FABER (703 Slovakia), Lukáš STEJSKAL, Michal KARAS (203 Czech Republic), Petra BĚLOHLÁVKOVÁ (203 Czech Republic), Hana KLAMOVÁ, Olga ČERNÁ, Eduard CMUNT (203 Czech Republic), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Tomáš HORŇÁK (703 Slovakia, belonging to the institution), Anežka KVETKOVÁ (703 Slovakia, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution), Adam SVOBODNÍK (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), O. VIEWIORKA, Regina DEMLOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

22. Pražské hematologické dny Hematologie 2022, Praha, 2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30205 Hematology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/22:00127206

Organization unit

Faculty of Medicine

Keywords in English

Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia

Abstract

V originále

Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela, Petra ČIČÁTKOVÁ, Edgar FABER, Lukáš STEJSKAL, Michal KARAS, Petra BĚLOHLÁVKOVÁ, Hana KLAMOVÁ, Olga ČERNÁ, Eduard CMUNT, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, O. VIEWIORKA, Regina DEMLOVÁ and Jiří MAYER. HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In 22. Pražské hematologické dny Hematologie 2022, Praha. 2022.

@proceedings{2233293,
   author = {Žáčková, Daniela and Čičátková, Petra and Faber, Edgar and Stejskal, Lukáš and Karas, Michal and Bělohlávková, Petra and Klamová, Hana and Černá, Olga and Cmunt, Eduard and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Viewiorka, O. and Demlová, Regina and Mayer, Jiří},
   booktitle = {22. Pražské hematologické dny Hematologie 2022, Praha},
   keywords = {Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia},
   language = {eng},
   title = {HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.},
   year = {2022}
}

TY  - CONF
ID  - 2233293
AU  - Žáčková, Daniela - Čičátková, Petra - Faber, Edgar - Stejskal, Lukáš - Karas, Michal - Bělohlávková, Petra - Klamová, Hana - Černá, Olga - Cmunt, Eduard - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Viewiorka, O. - Demlová, Regina - Mayer, Jiří
PY  - 2022
TI  - HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
KW  - Tyrosine Kinase Inhibitors' Discontinuation
KW  - Two-Step Dose Reduction
KW  - Chronic Myeloid Leukemia
N2  - Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.
ER  -

ŽÁČKOVÁ, Daniela, Petra ČIČÁTKOVÁ, Edgar FABER, Lukáš STEJSKAL, Michal KARAS, Petra BĚLOHLÁVKOVÁ, Hana KLAMOVÁ, Olga ČERNÁ, Eduard CMUNT, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, O. VIEWIORKA, Regina DEMLOVÁ and Jiří MAYER. HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In \textit{22. Pražské hematologické dny Hematologie 2022, Praha}. 2022.

Detailed Information on Publication Record